Although minimization of crystalloids is a widely adopted practice in the resuscitation of patients with severe hemorrhage, its direct impact on high-ratio resuscitation (HRR) outcomes has not been analyzed. We hypothesize that HRR patients will have worse outcomes from crystalloid use.
D
amage-control resuscitation (DCR) when use in combination with damage-control laparotomy (DCL) increases survival rates in patients with severe hemorrhage. 1Y4 Civilian and military studies have demonstrated a survival benefit when massive transfusion protocols (MTPs) incorporates high-ratio resuscitation (HRR) of fresh frozen plasma (FFP) to packed red blood cells (PRBCs) in this group of patients. 5Y9 Effective and aggressive incorporation of HRR is essential to correct the combination of metabolic acidosis, hypothermia, and acute coagulopathy of trauma shock (ACoTS) associated with severe tissue injury and tissue hypoperfusion.
Resuscitation strategies in patients with severe hemorrhage have evolved throughout the years. Military resuscitation during 1960s used aggressive crystalloid resuscitation with no predefined transfusion ratio of blood component therapy. Fluid administration focused on crystalloid use in an effort to balance inputs and outputs. 10, 11 This approach failed to address ACoTS in the severely injured patients with hemorrhagic shock.
Currently, one of the goals of DCR involves the early use of MTP with HRR, which consists of component therapy resuscitation that targets replacement of depleted blood volume, restoration of tissue perfusion, and effective correction of ACoTS. This resuscitation strategy has been accepted by many civilian trauma centers with overall improvement in outcomes.
5Y9,12Y14 The etiology leading to this overall improvement when using HRR could be multifactorial.
During HRR, FFP is matched to PRBC in a ratio close to 1:1 with conscious efforts in minimizing unnecessary crystalloid volume. Although minimization of crystalloids is a widely adopted practice in the resuscitation of patients with severe hemorrhage, data are lacking regarding the immediate and long-term impact of crystalloid volume to patients who received HRR. Our main goal in our multi-institutional analysis (MIA) was to specifically study the direct impact of crystalloid volume on MTP patients who received HRR with 10 or more units of PRBC. We hypothesize that overzealous use of crystalloid volume will dilute the benefits of HRR in this specific subset of patients.
PATIENTS AND METHODS
This was a 4-year (January 2007 to December 2010) institutional review boardYapproved retrospective MIA of patients who received MTP managed with DCL. A total of five Level I trauma centers were involved: The Spirit of Charity Hospital, New Orleans, Louisiana; San Francisco General Hospital, San Francisco, California; Oregon Health and Science University, Portland, Oregon; University of Southern California, Los Angeles, California; and University of Texas Health Science Center, Houston, Texas. Inclusion criteria included all adult trauma patients' with Injury Severity Score (ISS) of 15 or greater, patients who are 18 years or older who received more than 1 U of PRBC and underwent DCL. MTP activation and resuscitation ratios were based on each participating institution guidelines. Supplemental Digital Content 1 (http://links.lww.com/TA/A284) contains participating institutions' MTPs. Excluded were patients who died in the emergency department (ED) or in the operating room without surgical intervention, patients with traumatic brain injuries, and patients with incomplete documentation.
DCL was defined as a three-phase operative and critical care interventions. For the first phase, patients were taken to the operating room for an initial ''damage-control'' procedure serving only to control hemorrhage, prevent further contamination, and prevent further injury. For the second phase, patients were taken to the surgical intensive care unit for physiologic stabilization, including resuscitation, warming to correct hypothermia, and correction of acidosis and coagulopathy. For the third phase, patients were taken back to the operating room for a ''staged procedure'' (definitive surgical management). 2 Resuscitation ratios during the first 24 hours was defined and calculated as units of PRBC and units of FFP given in the ED and operating room during their first phase of DCL. Ratios of FFP/PRBC during that time frame were calculated based on the quantity of units of FFP to PRBC given and divided in two groups: HRR (1Y1:2) and low-ratio resuscitation (LRR G 1:2). Kaplan-Meier (KM) survival analysis was calculated between HRR and LRR groups for patients who received MTP with 10 or more units of PRBC. If survival benefit is demonstrated in HRR MTP patients who received MTP with 10 or more units of PRBC, subgroup analysis will focus on the immediate and long-term impact of crystalloid volume on HRR.
To evaluate our hypothesis, 24-hour crystalloid volume on HRR MTP patients who received 10 or more units of PRBC was further analyzed. Crystalloid volume during the first 24 hours was defined and calculated in liters (L) given in the ED and operating room during the first phase of DCL. HRR patients were separated into three groups according to 24-hour crystalloid volume received: (1) less than 5 L, (2) 5 L to 10 L, and (3) 10 L or greater. HRR MTP patients' demographics were analyzed between groups, and prevalence among groups was calculated. Demographics included anatomic, physiologic, and resuscitation variables. Anatomic variables are as follows: patient age (years), sex (%male), mechanism of injury (%penetrating), and ISS. Physiologic variables are as follows: ED systolic blood pressure (ED SBP, mm Hg), ED heart rate (ED HR, beats per minute [bpm]), ED shock index (ED SI), ED international normalized ratio (ED INR), and ED base deficit (ED BD). Resuscitation variables are as follows: 24-hour crystalloid volume (L), 24-hour FFP volume (U), 24-hour PRBC volume (U), 24-hour FFP/PRBC ratios, and hospital length of stay (LOS) (days). KM survival analysis in the HRR subgroups was computed to demonstrate differences in mortality based on 24-hour crystalloid volume.
HRR patients' complications were evaluated during each patient's LOS. The following complications were recorded: sepsis, bacteremia, urinary tract infection (UTI), ventilatorassociated pneumonia (VAP), surgical site infection (SSI), adult respiratory distress syndrome (ARDS), deep vein thrombosis (DVT), pulmonary embolism (PE), and acute renal failure (ARF). Sepsis was defined from the Surviving Sepsis Campaign guidelines. 15 ARDS was defined as bilateral pulmonary infiltrates noted on chest x-rays and severe hypoxemia (PaO 2 /FIO 2 ratio G 200). ARF was defined based on the RIFLE (Risk, Injury, Failure, Loss, and End-stage Kidney) classification. 16 To demonstrate if there is any increase likelihood in morbidity with 24-hour crystalloid infusion in any patient resuscitated with at least 1 U of PRBC, multivariate logistic regression odds ratios were calculated to evaluate its impact on morbidity. Furthermore, if any trend in increase likelihood of complication is demonstrated with 24-hour crystalloid infusion in any patient receiving at least more than 1 U of PRBC, a Fischer's exact test will be used to characterize the impact of 24-hour crystalloid volume on HRR patients with MTP of 10 or more units of PRBC. HRR MTP patients who received 10 or more units of PRBC were grouped based on 24-hour crystalloid volume to determine the direct impact of crystalloid volume on morbidity outcomes.
Statistical Analysis
Demographic characteristics, clinical parameters, morbidity, and mortality outcomes were investigated between 24-hour crystalloid volume groups. Demographics were summarized as mean (SD) and compared using analysis of variance. Morbidity outcomes for MTP patients were analyzed using multiple logistic regression, and odds ratio (OR) (95% confidence interval [CI]) was calculated. Fisher's exact was used to test for significance between 24-hour crystalloid volumes in HRR MTP patients who received 10 or more units of PRBC. Survival analysis was completed by using KM for mortality outcomes. Statistical significance was defined as p G 0.05. Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL) and SAS version 9.1.3 (Cary, NC).
RESULTS
During the 4-year analysis, a total of 1,484 patients received more than 1 U of PRBC, of which 827 patients did not meet inclusion criteria for analysis. Demographics were available for 657 patients (44.2%) who received more than 1 U of PRBC, of which 451 (68.6%) received MTP with 10 Table 1) . Of interest, 30-day KM survival curve for HRR MTP patients with 10 or more PRBCs showed no difference in survival between 24-hour crystalloid volume groups (log rank p = 0.524, Fig. 2B ).
Using multivariate logistic regression to evaluate the impact of 24-hour crystalloid volume on morbidity for patients who received at least more than 1 U of PRBC, crystalloid use was associated with increase odds for SSI (OR, 1.06; 95% CI, (Fig. 3) . After adjusting for all variables in our multiple logistic regression model in all MTP patients who received 10 or more units of PRBC, 24-hour crystalloid volume (OR, 1.11; 95% CI, 1.01Y2.59; p = 0.001), ED BD (OR, 1.02; 95% CI, 1.00Y1.10; p = 0.002), and ED SBP (OR, 1.19; 95% CI, 1.05Y4.33; p = 0.043) were predictors of increase morbidities, and HRR was not a predictor (OR 1.34; 95% CI, 0.93Y4.17; p = 0.065) (see Supplemental Digital Content 2, http://links.lww.com/TA/A285).
DISCUSSION
During the history of trauma resuscitation, crystalloids have been the standard of fluid resuscitation with ongoing recommendations of moderation and adaptations.
PRBC if transient or no response, when hemorrhagic shock is suspected. 19, 20 Hemorrhagic shock is the cause of death in up to 40% to 50% of trauma victims. 9 Using DCR, a survival benefit 5Y9 has been demonstrated in this subset of patients by integrating early HRR with the goal of a fixed transfusion ratio close to 1:1 of FFP/PRBC, restriction of crystalloid infusion, and principles of DCL. 1, 12 This target-oriented volume replacement therapy aims to correct hemodynamic stability, ACoTS, and tissue hypoperfusion associated with severe hemorrhage.
Our MIA support previous studies with a decreased mortality in HRR MTP patients transfused with 10 or more units of PRBC when compared with LRR. Although the majority of our patients were managed with HRR, the high prevalence of unnecessary use of 24-hour crystalloid volume needs further attention. Of significance, within all MTPs that received 10 or more units of PRBC, HRR was not a predictor of morbidity, but 24-hour crystalloid volume was. Although 
Perioperative Crystalloid Fluid Overload Causes Significant Morbidity
Traditional perioperative fluid management aims to fulfill physiologic requirements and to correct preoperative, intraoperative, and ongoing volume losses. Different phases of fluid resuscitation have been described for trauma patients, with specific rationales for each phase. In the immediate operative Phase I of DCL, volume loading with crystalloid to maintain preload and thus cardiac output is emphasized. After volume loading, other patient-specific objectives are addressed, for example, optimizing tissue perfusion, maintaining normothermia, and normalizing coagulation. This regimen does not address ACoTS in this group of patients with hemorrhagic shock but rather leads to massive volume infusions of isotonic crystalloid in the first 12 hours after trauma, as was the case in our study. 22, 23 This overzealous volume overload is particularly detrimental to DCL patients undergoing HRR, whose injuries can be exacerbated by overload states. 24 Fluid overload and the subsequent physiologic and immunologic cascades are particularly problematic for trauma patients with severe hemorrhage undergoing HRR. These patients have injuries, which make them susceptible to the devastating effects of volume overload as has been demonstrated in patients with traumatic closed head injuries and shock. DCL patients with blunt or penetrating traumatic abdominal injuries may be more susceptible to the fluid overload mechanisms leading to multiple system organ failure because of parenchymal or vascular insults to abdominal organs caused by trauma and hemorrhagic shock. Because of this, it is critical to examine fluid management for patients undergoing HRR, to dampen the deleterious effects of volume overload.
Following major trauma, a well-known systemic inflammatory response is activated, allowing an increase in capillary permeability. 25, 26 This further causes a decrease in osmotic 
pressure in the intravascular space resulting in a loss of fluid to the interstitial space. Resuscitation with unnecessary large crystalloid fluid volumes further potentiates cellular injury from imbalances occurring in extracellular and intracellular osmolarity. 27 With massive fluid shifts, previously described cellular regulatory mechanisms become overwhelmed, and resultant dysregulation of cellular mechanisms occurs including cytosolic acidification, dilution of cellular proteins, and inactivation of protein kinases. 28 The problematic fluid shifts manifest, systemically causing pulmonary and cardiac complications, 29 abdominal compartment syndrome, 30, 31 coagulation disturbances, 32Y35 and immunologic and inflammatory mediator dysfunction. 36 Within all MTPs that received 10 or more units of PRBC in our logistic regression model, HRR was not a predictor of morbidity, but 24-hour crystalloid volume was. In addition, higher volumes of crystalloid in this subset of patients demonstrated increased incidence of complications (OR, 1.11; 95% CI, 1.01Y2.59; p = 0.001). This increased in complications was fourfold once the 24-hour volume of crystalloids was 5 L to 10 L (158%) when compared with less than 5 L (36.8%). Taking into consideration the multitude of detrimental effects related to crystalloid administration, an essential goal of HRR MTPs should be to minimize crystalloid use in patients with severe hemorrhage. Based on our results, improved overall outcomes were seen in patients with severe hemorrhage resuscitated with HRR when they received (1) less 24-hour crystalloid volume and (2) a greater quantity of FFP per unit of PRBC. This finding suggests not only a deleterious impact of 24-hour crystalloid volume but also perhaps a therapeutic effect of FFP when used during HRR (Fig. 3) .
Therapeutic Effects of FFP during HRR
There are many therapeutic effects of FFP in the setting of hemorrhagic resuscitation in addition to simply replacing coagulation factors and correcting coagulopathy. In several animal studies, FFP has been shown to be less inflammatory compared with both crystalloid and colloid fluid in addition to being associated with fewer complications. 37, 38 In our study, HRR MTP patients with 10 or more units of PRBC in all crystalloid groups showed a consistent 24-hour volume of PRBC. Of interest, the 24-hour volume of FFP and its HRR to PRBC decreased, while 24-hour crystalloid volume use increased. Patients with the lowest HRR of FFP/PRBC received the greatest amount of 24-hour crystalloid volume and had a fourfold increase incidence of complications when the volume was 5 L to 10 L. This finding raises the question regarding not only the potential detrimental effect of overzealous crystalloid use but also the potential true therapeutics benefits in endothelial protection of FFP during HRR.
The benefits of FFP are hypothesized by Pati et al. 39 to include a mechanism at the cellular level in combination of the replacement of coagulation factors. In their biologic mechanism model, hemorrhagic shock induces hypoxia, endothelial cell tight junction breakdown, inflammation, and leukocyte diapedesis. The data in vivo and in vitro suggest that FFP has beneficial effects on vascular endothelial stability and resuscitation that are independent of its effects on hemostasis. They concluded that FFP repairs and ''normalizes'' the vascular endothelium by restoring tight junctions, building the glycocalyx, and inhibiting inflammation and edema, while crystalloid infusion will only potentiate vascular endothelial injury further.
Study Limitations
There are several limitations to this study. It is a large retrospective MIA, and the data lack certain aspects of medical and surgical history, which could be relevant to the resuscitation of patients with severe hemorrhage, including potential impact of prehospital crystalloid and PRBCs administered on final outcomes. Various institutional triage and acute care management were not controlled in this study, and it may account for significant differences in outcome as well. In addition, although our MIA provides a convenience sample, the data are susceptible to bias in patient selection, inconsistency in 24-hour crystalloid volume measurement, inconsistency in transfusion ratios, and lack of proper documentation of clinical variables between facilities, and missing data.
CONCLUSION
The results from this current study highlight the complications associated with overzealous use of 24-hour crystalloid during HRR in patients with severe hemorrhage. The abundant evidence demonstrating improved outcomes with HRR has led to MTPs including specific guidelines and standards for ratios of FFP and PRBC. According to recent studies, 24, 40 including this MIA, the direct deleterious longterm effect of 24-hour crystalloid volume on HRR should be emphasized. Perhaps, future additions to MTPs will be standardized to include purposeful measures minimizing use of 24-hour crystalloids. New guidelines within MTPs emphasizing Figure 3 . The use of FFP and its ratio to PRBC decreased, while crystalloid use increased. Patients with the lowest HRR ratio received the least amount of FFP with concomitant greatest amount of crystalloids. This group had the highest incidence of complications.
